{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:22:49Z","timestamp":1786994569525,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","nanomedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.nano.2016.08.006","type":"journal-article","created":{"date-parts":[[2016,8,23]],"date-time":"2016-08-23T04:45:48Z","timestamp":1471927548000},"page":"411-420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine"],"prefix":"10.1016","volume":"13","author":[{"given":"Pierre-Louis","family":"Herv\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Deloizy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphyne","family":"Descamps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Anne","family":"Rameix-Welti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Fix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason S.","family":"McLellan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"El\u00e9ou\u00ebt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Riffault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nano.2016.08.006_bb0005","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.virusres.2011.09.020","article-title":"Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years","volume":"162","author":"Collins","year":"2011","journal-title":"Virus Res"},{"key":"10.1016\/j.nano.2016.08.006_bb0010","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/bmb\/61.1.13","article-title":"The pathogenesis of respiratory syncytial virus disease in childhood","volume":"61","author":"McNamara","year":"2002","journal-title":"Br Med Bull"},{"key":"10.1016\/j.nano.2016.08.006_bb0015","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nm.1894","article-title":"Lack of antibody affinity maturation due to poor toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease","volume":"15","author":"Delgado","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.nano.2016.08.006_bb0020","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1128\/JVI.63.7.2941-2950.1989","article-title":"Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function","volume":"63","author":"Beeler","year":"1989","journal-title":"J Virol"},{"key":"10.1016\/j.nano.2016.08.006_bb0025","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40121-014-0046-6","article-title":"Safety and effectiveness of palivizumab in children at high risk of serious disease due to respiratory syncytial virus infection: a systematic review","author":"Wegzyn","year":"2014","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.nano.2016.08.006_bb0030","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1542\/peds.102.3.531","article-title":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants","volume":"102","author":"The IMpact-RSV Study Group","year":"1998","journal-title":"Pediatrics"},{"issue":"Pt 9","key":"10.1016\/j.nano.2016.08.006_bb0035","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1099\/0022-1317-73-9-2217","article-title":"Protective epitopes on the fusion protein of respiratory syncytial virus recognized by murine and bovine monoclonal antibodies","volume":"73","author":"Taylor","year":"1992","journal-title":"J Gen Virol"},{"key":"10.1016\/j.nano.2016.08.006_bb0040","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1099\/0022-1317-73-9-2225","article-title":"Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial","volume":"73","author":"Arbiza","year":"1992","journal-title":"J Gen Virol"},{"key":"10.1016\/j.nano.2016.08.006_bb0045","doi-asserted-by":"crossref","first-page":"7970","DOI":"10.1128\/JVI.00447-10","article-title":"Neutralization of human respiratory syncytial virus infectivity by antibodies and low-molecular-weight compounds targeted against the fusion glycoprotein","volume":"84","author":"Magro","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.nano.2016.08.006_bb0050","doi-asserted-by":"crossref","first-page":"9619","DOI":"10.1073\/pnas.1106536108","article-title":"Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers","volume":"108","author":"Swanson","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nano.2016.08.006_bb0055","doi-asserted-by":"crossref","first-page":"7788","DOI":"10.1128\/JVI.00555-11","article-title":"Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes","volume":"85","author":"McLellan","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.nano.2016.08.006_bb0060","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.coviro.2015.03.002","article-title":"Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein","volume":"11","author":"McLellan","year":"2015","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.nano.2016.08.006_bb0065","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nsmb.1723","article-title":"Structural basis of respiratory syncytial virus neutralization by motavizumab","volume":"17","author":"McLellan","year":"2010","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.nano.2016.08.006_bb0070","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1099\/0022-1317-74-12-2567","article-title":"Conformational constraints of conserved neutralizing epitopes from a major antigenic area of human respiratory syncytial virus fusion glycoprotein","volume":"74","author":"Lopez","year":"1993","journal-title":"J Gen Virol"},{"key":"10.1016\/j.nano.2016.08.006_bb0075","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jmb.2011.04.044","article-title":"Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus","volume":"409","author":"McLellan","year":"2011","journal-title":"J Mol Biol"},{"key":"10.1016\/j.nano.2016.08.006_bb0080","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nature12966","article-title":"Proof of principle for epitope-focused vaccine design","volume":"507","author":"Correia","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.nano.2016.08.006_bb0085","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1016\/j.vaccine.2016.03.109","article-title":"Advances in RSV vaccine research and development \u2013 a global agenda","volume":"34","author":"Higgins","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.nano.2016.08.006_bb0090","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1016\/S0264-410X(03)00355-4","article-title":"Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies","volume":"21","author":"Piedra","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.nano.2016.08.006_bb0095","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1128\/JVI.69.11.6658-6664.1995","article-title":"Role of T-lymphocyte subsets in recovery from respiratory syncytial virus infection in calves","volume":"69","author":"Taylor","year":"1995","journal-title":"J Virol"},{"key":"10.1016\/j.nano.2016.08.006_bb0100","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.molimm.2014.12.004","article-title":"Immunology of bovine respiratory syncytial virus in calves","volume":"66","author":"Guzman","year":"2015","journal-title":"Mol Immunol"},{"key":"10.1016\/j.nano.2016.08.006_bb0105","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1099\/vir.0.82282-0","article-title":"The nine C-terminal amino acids of the respiratory syncytial virus protein P are necessary and sufficient for binding to ribonucleoprotein complexes in which six ribonucleotides are contacted per N protein protomer","volume":"88","author":"Tran","year":"2007","journal-title":"J Gen Virol"},{"key":"10.1016\/j.nano.2016.08.006_bb0110","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1126\/science.1177634","article-title":"Crystal structure of a nucleocapsid-like nucleoprotein-RNA complex of respiratory syncytial virus","volume":"326","author":"Tawar","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.nano.2016.08.006_bb0115","doi-asserted-by":"crossref","first-page":"e1766","DOI":"10.1371\/journal.pone.0001766","article-title":"Sub-nucleocapsid nanoparticles: a nasal vaccine against respiratory syncytial virus","volume":"3","author":"Roux","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.nano.2016.08.006_bb0120","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1016\/j.vaccine.2010.03.008","article-title":"A new subunit vaccine based on nucleoprotein nanoparticles confers partial clinical and virological protection in calves against bovine respiratory syncytial virus","volume":"28","author":"Riffault","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.nano.2016.08.006_bb0125","doi-asserted-by":"crossref","first-page":"e100392","DOI":"10.1371\/journal.pone.0100392","article-title":"Vaccine safety and efficacy evaluation of a recombinant bovine respiratory syncytial virus (BRSV) with deletion of the SH gene and subunit vaccines based on recombinant human RSV proteins: N-nanorings, P and M2-1, in calves with maternal antibodies","volume":"9","author":"Blod\u00f6rn","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.nano.2016.08.006_bb0130","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1128\/JVI.01141-13","article-title":"A novel subnucleocapsid nanoplatform for mucosal vaccination against influenza virus that targets the ectodomain of matrix protein 2","volume":"88","author":"Herv\u00e9","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.nano.2016.08.006_bb0135","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1099\/vir.0.79830-0","article-title":"Biochemical characterization of the respiratory syncytial virus P\u2013P and P\u2013N protein complexes and localization of the P protein oligomerization domain","volume":"85","author":"Castagne","year":"2004","journal-title":"J Gen Virol"},{"key":"10.1016\/j.nano.2016.08.006_bb0140","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.provac.2009.07.026","article-title":"Adjuvant formulation for veterinary vaccines: Montanide\u2122 gel safety profile","volume":"1","author":"Parker","year":"2009","journal-title":"Procedia Vaccinol"},{"key":"10.1016\/j.nano.2016.08.006_bb0145","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1038\/ncomms6104","article-title":"Visualizing the replication of respiratory syncytial virus in cells and in living mice","volume":"5","author":"Rameix-Welti","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.nano.2016.08.006_bb0150","doi-asserted-by":"crossref","first-page":"15018","DOI":"10.1038\/mtm.2015.18","article-title":"Mucosal delivery of a vectored RSV vaccine is safe and elicits protective immunity in rodents and nonhuman primates","volume":"2","author":"Pierantoni","year":"2015","journal-title":"Mol Ther - Methods Clin Dev"},{"key":"10.1016\/j.nano.2016.08.006_bb0155","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1172\/JCI78450","article-title":"Palivizumab epitope\u2013displaying virus-like particles protect rodents from RSV challenge","volume":"125","author":"Schickli","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nano.2016.08.006_bb0160","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.4049\/jimmunol.0803115","article-title":"Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat\/Env compared with multigenic vaccines","volume":"182","author":"Florese","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.nano.2016.08.006_bb0165","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature06106","article-title":"Fc receptor but not complement binding is important in antibody protection against HIV","volume":"449","author":"Hessell","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.nano.2016.08.006_bb0170","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.4049\/jimmunol.172.9.5598","article-title":"Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity","volume":"172","author":"Jegerlehner","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.nano.2016.08.006_bb0175","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.4049\/jimmunol.0902147","article-title":"Universal vaccine based on ectodomain of matrix protein 2 of influenza A: fc receptors and alveolar macrophages mediate protection","volume":"186","author":"El Bakkouri","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.nano.2016.08.006_bb0180","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1126\/science.1234914","article-title":"Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody","volume":"340","author":"McLellan","year":"2013","journal-title":"Science"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963416301149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963416301149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T08:32:17Z","timestamp":1601022737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963416301149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S1549963416301149"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2016.08.006","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2016.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}